×
About 53,413 results

ALLMedicine™ Anemia Center

Research & Reviews  16,781 results

Clinical observation of low-dose combination chemotherapy in refractory/recurrent parox...
https://doi.org/10.1002/jcla.24239
Journal of Clinical Laboratory Analysis; Li L, Liu H et. al.

Jan 15th, 2022 - We performed a retrospective analysis to investigate the clinical characteristics and therapeutic strategies of 20 refractory/recurrent PNH patients, including the clinical efficacy of chemotherapy treatment, safety, and survival. The clinical dat...

Associations between Autoimmune Conditions and Gastric Cancer Risk among Elderly Adults...
https://doi.org/10.14309/ajg.0000000000001622
The American Journal of Gastroenterology; Song M, Camargo MC et. al.

Jan 15th, 2022 - Pernicious anemia (PA) is a risk factor for gastric cancer. Other autoimmune conditions may also contribute. In a case-control study, we evaluated 47 autoimmune conditions among 35,499 gastric cancers and 200,000 cancer-free controls. Six conditio...

Evaluating test utilization for anemia during pregnancy.
https://doi.org/10.1111/ijlh.13797
International Journal of Laboratory Hematology; Santana G, Reise R et. al.

Jan 15th, 2022 - To evaluate, using longitudinal laboratory data, potential care gaps, and the prevalence of anemia in pregnant women residing in New Mexico, USA. A total of 985 pregnant women aged 13-60 were included from December 1, 2018 to December 1, 2019. Par...

Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymp...
https://doi.org/10.1200/JCO.21.02321
Journal of Clinical Oncology : Official Journal of the Am... Giné E, de la Cruz F et. al.

Jan 15th, 2022 - The need for an individualized management of indolent clinical forms in mantle cell lymphoma (MCL) is increasingly recognized. We hypothesized that a tailored treatment with ibrutinib in combination with rituximab (IR) could obtain significant res...

see more →

Guidelines  25 results

Controversies in optimal anemia management: conclusions from a Kidney Disease: Improvin...
https://doi.org/10.1016/j.kint.2021.03.020
Kidney International; Babitt JL, Eisenga MF et. al.

Apr 12th, 2021 - In chronic kidney disease, anemia and disordered iron homeostasis are prevalent and associated with significant adverse consequences. In 2012, Kidney Disease: Improving Global Outcomes (KDIGO) issued an anemia guideline for managing the diagnosis,...

Spotlight: Gastrointestinal Evaluation of Iron Deficiency Anemia.
https://doi.org/10.1053/j.gastro.2020.08.036
Gastroenterology Ko CW, Siddique SM et. al.

Aug 31st, 2020 - Spotlight: Gastrointestinal Evaluation of Iron Deficiency Anemia.|2020|Ko CW,Siddique SM,Patel A,Harris A,Altayar O,|blood,diagnosis,etiology,standards,standards,standards,diagnostic imaging,metabolism,pathology,standards,blood,complications,diagn...

GI Evaluation of Iron Deficiency Anemia: Clinical Decision Support Tool.
https://doi.org/10.1053/j.gastro.2020.08.043
Gastroenterology

Aug 31st, 2020 - GI Evaluation of Iron Deficiency Anemia: Clinical Decision Support Tool.|2020| ,|blood,diagnosis,etiology,standards,methods,standards,standards,diagnostic imaging,metabolism,pathology,standards,blood,complications,diagnosis,pathology,analysis,diag...

AGA Clinical Practice Guidelines on the Gastrointestinal Evaluation of Iron Deficiency ...
https://doi.org/10.1053/j.gastro.2020.06.046
Gastroenterology Ko CW, Siddique SM et. al.

Aug 19th, 2020 - AGA Clinical Practice Guidelines on the Gastrointestinal Evaluation of Iron Deficiency Anemia.|2020|Ko CW,Siddique SM,Patel A,Harris A,Sultan S,|blood,diagnosis,epidemiology,etiology,standards,standards,diagnostic imaging,metabolism,pathology,stan...

Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH...
https://doi.org/10.1200/JCO.18.02142
Journal of Clinical Oncology : Official Journal of the Am... Bohlius J, Bohlke K et. al.

Apr 11th, 2019 - To update the American Society of Clinical Oncology (ASCO)/American Society of Hematology (ASH) recommendations for use of erythropoiesis-stimulating agents (ESAs) in patients with cancer. PubMed and the Cochrane Library were searched for randomiz...

see more →

Drugs  731 results see all →

Clinicaltrials.gov  943 results

Lidocaine in ERAS for FESS
https://clinicaltrials.gov/ct2/show/NCT03047070

Jan 14th, 2022 - Functional endoscopic sinus surgery (FESS) is a commonly performed procedure in the head and neck field. It is known that bleeding during FESS can affect directly to the visibility of safe landmarks and surgical outcomes. Use of vasoactive drugs t...

Dietary Intake, Health and Micronutrient Status in Haiti
https://clinicaltrials.gov/ct2/show/NCT04034381

Jan 14th, 2022 - Women of reproductive age and young children are especially vulnerable to micronutrient deficiencies which may lead to life-long disabilities. In Haiti, deficiencies in micronutrients such as iron, zinc, and vitamin A, are likely prevalent, but re...

Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma
https://clinicaltrials.gov/ct2/show/NCT04933539

Jan 14th, 2022 - Background: Smoldering multiple myeloma (SMM) is a precursor condition to MM defined by the clinical parameters of M-protein >=3.0 g/dL or bone marrow plasma cells >=10%, and absence of end organ disease. Patients with high-risk SMM have a risk of...

Quality Assurance on Anemia Management in Patients With Solid Tumors and Malignant Lymphoma
https://clinicaltrials.gov/ct2/show/NCT05190263

Jan 13th, 2022 - Health care structure analysis and recruitment (phase 1): In a first step, data on care facilities treating patients in the above indica-tions in Germany will be collected (gastroenterology, gynecology, hema-tology/oncology, and pneumology hospita...

A Study to Learn More About the Long-term Safety and Effectiveness of Molidustat as a Treatment for Japanese Men and Women With Renal Anemia
https://clinicaltrials.gov/ct2/show/NCT04899661

Jan 12th, 2022 - In this study, the researchers want to learn more about the safety and effectiveness of Molidustat in Japanese men and women who have renal anemia, a condition in which the kidneys do not make enough of a hormone that helps the body make new red b...

see more →

News  2,757 results

FDA Accepts BLA for Tislelizumab in Esophageal Squamous Cell Carcinoma
https://www.onclive.com/view/fda-accepts-bla-for-tislelizumab-in-esophageal-squamous-cell-carcinoma

Jan 14th, 2022 - The FDA has accepted for review a biologics license application (BLA) for tislelizumab (BGB-A317) as a potential therapeutic option in patients with unresectable recurrent locally advanced or metastatic esophageal squamous cell carcinoma (ESCC) fo...

Ibrutinib/Rituximab Combo Represents Effective Chemo-Free Option for Elderly Patients with MCL
https://www.onclive.com/view/ibrutinib-rituximab-combo-represents-effective-chemo-free-option-for-elderly-patients-with-mcl

Jan 14th, 2022 - The combination of ibrutinib (Imbruvica) and rituximab (Rituxan) produced a high overall response rate (ORR) and durable survival in elderly patients with mantle cell lymphoma (MCL), according to data from a phase 2 ENRICH trial (NCT0180567) publi...

Fast Five Quiz: Relapsed/Refractory Multiple Myeloma
https://www.medscape.com/viewarticle/962961

Jan 11th, 2022 - Multiple myeloma is a plasma cell cancer characterized by proliferation of monoclonal plasma cells in bone marrow, leading to an overabundance of monoclonal paraprotein (M protein), destruction of bone, and displacement of other hematopoietic cell...

Aspacytarabine Shows Efficacy, Safety in Newly Diagnosed AML Unfit for Intensive Therapy
https://www.onclive.com/view/aspacytarabine-shows-efficacy-safety-in-newly-diagnosed-aml-unfit-for-intensive-therapy

Jan 10th, 2022 - The novel antimetabolite aspacytarabine (BST-236) was found to produce a complete remission (CR) rate of 37% in adult patients with newly diagnosed acute myeloid leukemia (AML) who are unfit for intensive therapy, according to data from a phase 2b...

FDA Grants Fast Track Designation to Enobosarm for AR+/ER+ Metastatic Breast Cancer
https://www.onclive.com/view/fda-grants-fast-track-designation-to-enobosarm-for-ar-er-metastatic-breast-cancer

Jan 10th, 2022 - The FDA has granted a fast track designation to enobosarm as a potential therapeutic option for patients with androgen receptor (AR)–positive, estrogen receptor (ER)–positive, HER2-negative, metastatic breast cancer who progressed on a nonsteroida...

see more →

Patient Education  128 results see all →